Format

Send to

Choose Destination
Ci Ji Yi Xue Za Zhi. 2018 Jul-Sep;30(3):141-147. doi: 10.4103/tcmj.tcmj_71_18.

Treatment of acute bipolar depression.

Author information

1
Department of Psychiatry, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.
2
School of Medicine, Tzu Chi University, Hualien, Taiwan.

Abstract

Depression is the predominant pole of disability in bipolar disorder and compared with mania/hypomania, has less systematic research guiding the development of treatment especially in its acute phase (acute bipolar depression). The deficiency in the management of the acute bipolar depression largely reflects the natural divergence of opinion resulting from significant knowledge gaps. At present, there are only 3 approved drug treatments for acute bipolar depression: olanzapine/fluoxetine combination, quetiapine (immediate or extended release), and lurasidone (monotherapy or adjunctive to lithium or valproate). Nonapproved agents and nonpharmacologic treatment such as lamotrigine, antidepressants, modafinil, pramipexole, ketamine, and electroconvulsive therapy are often prescribed to treat acute bipolar depression. This article discusses the challenges of diagnosing bipolar depression, and reviews above treatment options for acute bipolar depression.

KEYWORDS:

Acute bipolar depression; Lurasidone; Olanzapine/fluoxetine combination; Quetiapine

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center